The DOI matches its Crossref record.
Examination of Several Potential Mechanisms for the Negative Outcome in a Clinical Stroke Trial of Enlimomab, a Murine Anti-Human Intercellular Adhesion Molecule-1 Antibody: A Bedside-to-Bench Study
Abstract
BACKGROUND AND PURPOSE: Enlimomab, a murine monoclonal anti-human intercellular adhesion molecule (ICAM)-1 antibody, had a negative outcome in a multicenter acute-stroke trial. We did a bedside-to-bench study in standardized rat stroke models to explore mechanisms for these untoward results. METHODS: After focal brain ischemia in Wistar rats and spontaneously hypertensive rats (SHR), we administered murine anti-rat ICAM-1 antibody (1A29), subclass-matched murine immunoglobulin (IgG1), or vehicle intravenously. To examine whether rat anti-mouse antibodies were generated against the mouse protein and whether these were deleterious, we sensitized Wistar rats with 1A29 or vehicle 7 days before surgery. Infarct volume, tissue myeloperoxidase activity, neutrophil CD11b expression, and microvascular E-selectin, P-selectin, and ICAM-1 expression were examined 48 hours after surgery. Complement activation was serially assessed for 2 hours after a single injection of either 1A29 or vehicle. RESULTS: 1A29 treatment did not significantly reduce infarct size in either strain. 1A29 sensitization augmented infarct size and generated rat anti-mouse antibodies. Although 1A29 inhibited neutrophil trafficking shown by reduction in brain myeloperoxidase activity, circulating neutrophils were activated and displayed CD11b upregulation. Complement was activated in 1A29-sensitized Wistar rats and 1A29-treated SHR. E-selectin (SHR), endothelial P-selectin (Wistar and SHR), and ICAM-1 (SHR) were upregulated in animals treated with 1A29. CONCLUSIONS: Administration to rats of a murine antibody preparation against ICAM-1, 1A29, elicits the production of host antibodies against the protein, activation of circulating neutrophils, complement activation, and sustained microvascular activation. These observations provide several possible mechanisms for central nervous system-related clinical deterioration that occurred when Enlimomab was given in acute ischemic stroke.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The immunology of stroke: from mechanisms to translation
Iadecola, C., & Anrather, J. (2011) · Nature Medicine · doi:10.1038/nm.2399 · Cited by 2,596
“In the case of the ICAM-1 trial, the negative outcome has been attributed to deleterious immunoactivation resulting from administration of a mouse antibody to humans, as reproduced in an experimental study in which mouse antibodies to rat ICAM-1 were administered to rat”
BackgroundMechanisms, challenges and opportunities in stroke
Lo, E. H., Dalkara, T., & Moskowitz, M. A. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1106 · Cited by 1,781
Neuroprotection for ischemic stroke: Past, present and future
Ginsberg, M. D. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.12.007 · Cited by 779
The Blood-Brain Barrier in Brain Homeostasis and Neurological Diseases
Weiss, N., Miller, F., Cazaubon, S., & Couraud, P.-O. (2009) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2008.10.022 · Cited by 731
Targeting Neutrophils in Ischemic Stroke: Translational Insights from Experimental Studies
Jickling, G. C., Liu, D., Ander, B. P., Stamova, B., Zhan, X., & Sharp, F. R. (2015) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.45 · Cited by 644
Pathophysiology, treatment, and animal and cellular models of human ischemic stroke
Woodruff, T. M., Thundyil, J., Tang, S.-C., Sobey, C. G., Taylor, S. M., & Arumugam, T. V. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-11 · Cited by 598
Stroke and the immune system: from pathophysiology to new therapeutic strategies
Macrez, R., Ali, C., Toutirais, O., Le Mauff, B., Defer, G., Dirnagl, U., & Vivien, D. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70066-7 · Cited by 560
Inflammatory Mechanisms after Ischemia and Stroke
Danton, G. H., & Dietrich, W. D. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.2.127 · Cited by 551
Brain Endothelial Cell-Cell Junctions: How to “Open” the Blood Brain Barrier
Stamatovic, S., Keep, R., & Andjelkovic, A. (2008) · Current Neuropharmacology · doi:10.2174/157015908785777210 · Cited by 513
Cerebral ischemia and inflammation
Iadecola, C., & Alexander, M. (2001) · Current Opinion in Neurology · doi:10.1097/00019052-200102000-00014 · Cited by 466
Post‐ischemic brain damage: pathophysiology and role of inflammatory mediators
Amantea, D., Nappi, G., Bernardi, G., Bagetta, G., & Corasaniti, M. T. (2009) · The FEBS Journal · doi:10.1111/j.1742-4658.2008.06766.x · Cited by 459
Acute ischaemic stroke and infection: recent and emerging concepts
Emsley, H. C., & Hopkins, S. J. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70061-9 · Cited by 416
The HMGB1 Receptor RAGE Mediates Ischemic Brain Damage
Muhammad, S., Barakat, W., Stoyanov, S., Murikinati, S., Yang, H., Tracey, K. J., Bendszus, M., Rossetti, G., Nawroth, P. P., Bierhaus, A., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.2435-08.2008 · Cited by 412
Inflammatory Cell Adhesion Molecules in Ischemic Cerebrovascular Disease
Frijns, C. J. M., & Kappelle, L. J. (2002) · Stroke · doi:10.1161/01.str.0000021902.33129.69 · Cited by 390
Immune interventions in stroke
Fu, Y., Liu, Q., Anrather, J., & Shi, F.-D. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.144 · Cited by 383
Pathogenesis of acute stroke and the role of inflammasomes
Fann, D. Y.-W., Lee, S.-Y., Manzanero, S., Chunduri, P., Sobey, C. G., & Arumugam, T. V. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2013.09.004 · Cited by 335
Cell adhesion molecules and ischemic stroke
Yilmaz, G., & Granger, D. N. (2008) · Neurological Research · doi:10.1179/174313208x341085 · Cited by 276
Inflammation and Infection in Clinical Stroke
Emsley, H. C. A., & Tyrrell, P. J. (2002) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200212000-00001 · Cited by 276
Justicia, C., Panés, J., Solé, S., Cervera, Á., Deulofeu, R., Chamorro, Á., & Planas, A. M. (2003) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/01.wcb.0000090680.07515.c8 · Cited by 262
Lopes Pinheiro, M. A., Kooij, G., Mizee, M. R., Kamermans, A., Enzmann, G., Lyck, R., Schwaninger, M., Engelhardt, B., & de Vries, H. E. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.10.018 · Cited by 247
Enzmann, G., Mysiorek, C., Gorina, R., Cheng, Y.-J., Ghavampour, S., Hannocks, M.-J., Prinz, V., Dirnagl, U., Endres, M., Prinz, M., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-012-1076-3 · Cited by 225
Blood–Brain Barrier Breakdown in Alzheimer’s Disease: Mechanisms and Targeted Strategies
Alkhalifa, A. E., Al-Ghraiybah, N. F., Odum, J., Shunnarah, J. G., Austin, N., & Kaddoumi, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216288 · Cited by 212
Development of Novel Therapeutics Targeting the Blood–Brain Barrier: From Barrier to Carrier
Li, J., Zheng, M., Shimoni, O., Banks, W. A., Bush, A. I., Gamble, J. R., & Shi, B. (2021) · Advanced Science · doi:10.1002/advs.202101090 · Cited by 202
Circulating adhesion molecules in obstructive sleep apnea and cardiovascular disease
Pak, V. M., Grandner, M. A., & Pack, A. I. (2014) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2013.01.002 · Cited by 43
Metadata
- Authors
- Furuya, K., Takeda, H., Azhar, S., McCarron, R. M., Chen, Y., Ruetzler, C. A., Wolcott, K. M., DeGraba, T. J., Rothlein, R., Hugli, T. E., del Zoppo, G. J., & Hallenbeck, J. M.
- Venue
- Stroke
- Published
- 2001-11-01
- Volume
- 32
- Issue
- 11
- Pages
- 2665-2674
- ISSN
- 0039-2499 (ISSN-L)
- 1524-4628
- OpenAlex
- W2094163321
- Cited by
- 171
- References
- 0
- FWCI
- 6.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.